EUVIMEDEUVIMED entdecken
Open Access · CC0

N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses

Durbadal Ojha, Collin S Hill, Shuntai Zhou, Alyssa Evans, Jacqueline M Leung, Christine A Schneider, Franck Amblard, Tyson A Woods, Raymond F Schinazi, Ralph S Baric, Karin E Peterson, Ronald Swanstrom iD

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1012574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Durbadal Ojha und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Insti…. Hauptthemen laut MEDLINE: Antiviral Agents, Cytidine, Virus Replication, La Crosse virus. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIEHS NIH HHS, NIAID NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strategy of lethal mutagenesis to limit virus replication. We evaluated ribavirin (RBV), favipiravir (FAV) and N 4 -hydroxycytidine (NHC) against La Crosse virus (LACV), which is one of the most common causes of pediatric arboviral encephalitis cases in North America and serves as a model for viral CNS invasion during acute infection. NHC was approximately 3 to 170 times more potent than RBV or FAV in neuronal cells. Oral administration of molnupiravir (MOV), the prodrug of NHC, decreased neurological disease development (assessed as limb paralysis, ataxia and weakness, repeated seizures, or death) by 31% (4 mice survived out of 13) when treatment was started on the day of infection. MOV also reduced disease by 23% when virus was administered intranasally (IN). NHC and MOV produced less fit viruses by incorporating predominantly G to A or C to U mutations. Furthermore, NHC also inhibited virus production of two other orthobunyaviruses, Jamestown Canyon virus and Cache Valley virus. Collectively, these studies indicate that NHC/MOV has therapeutic potential to inhibit viral replication and subsequent neurological disease caused by orthobunyaviruses and potentially as a generalizable strategy for treating acute viral encephalitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCytidineVirus ReplicationLa Crosse virusAnimalsMiceMutationRibavirinPyrazinesHydroxylaminesAmidesEncephalitis, CaliforniaHumansFemale

Substanzen

molnupiravirAntiviral AgentsN(4)-hydroxycytidineCytidinefavipiravirRibavirinPyrazinesHydroxylaminesAmides

Autor:innen und Institutionen

  • Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Hamilton, Montana, United States of America.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Hamilton, Montana, United States of America.
  • Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, United States of America.
  • Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Ronald Swanstrom

Förderung

  • NIEHS NIH HHS
  • NIAID NIH HHS
  • Intramural NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • NIH

Zitieren

APA

Ojha, D., Hill, C. S., Zhou, S., Evans, A., Leung, J. M., Schneider, C. A., Amblard, F., Woods, T. A., Schinazi, R. F., Baric, R. S., Peterson, K. E., & Swanstrom, R. (2024). N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012574

Vancouver

Ojha D, Hill CS, Zhou S, Evans A, Leung JM, Schneider CA, et al. N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012574

BibTeX
@article{Ojha2024,
  author = {Ojha, Durbadal and Hill, Collin S and Zhou, Shuntai and Evans, Alyssa and Leung, Jacqueline M and Schneider, Christine A and Amblard, Franck and Woods, Tyson A and Schinazi, Raymond F and Baric, Ralph S and Peterson, Karin E and Swanstrom, Ronald},
  title = {N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1012574}
}
Kostenlos starten →